Curis, Inc. (NASDAQ: CRIS), a drug development company, is focused on utilizing its innovative signaling pathway drug technologies to discover new targeting small molecule drug candidates for cancer. Through the expansion of its drug development efforts in the field of cancer, the company is building upon its previous experiences in targeting signaling pathways to develop next generation targeted cancer therapies. For further information, visit the Company’s web site at www.curis.com.
- 18 years ago
QualityStocks
Curis, Inc. (NASDAQ: CRIS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…